Convalescent Plasma Therapy: The Early Use in Moderate to Severe COVID-19 Patients in Hospitals with Limited Resources
Downloads
COVID-19 cases in Indonesia in the period of June-July 2021 showed a catastrophic spike. During this period, a recently discovered variant, the delta variant, appeared to be one of the sources of COVID-19 infection. Treatment modalities are limited due to reduced stock of drugs. A case of a 63-year-old man has been reported, with a history of having been vaccinated with two doses of Sinovac, experiencing moderate-to-severe symptoms of COVID-19 infection then given convalescent plasma therapy since his initial admission to the hospital. Three days after being given convalescent plasma therapy, the improvement was noticeable. Shortness of breath, cough, fever, and weakness were less complained. On the seventh day the patient fully recovered and got discharged. Convalescent plasma therapy was e ective in early stage and was able to improve outcomes. Indonesia needs sucient stocks of convalescent plasma as a therapy to overcome the limitations of medicines.
Dyer O. Covid-19 : Indonesia becomes Asia ' s new pandemic epicentre as delta variant spreads. 2021;(July):2021.
Fischer JC, Zänker K, Van Griensven M, Schneider M, Kindgen-Milles D, Knoefel WT, et al. The role of passive immunization in the age of SARS-CoV-2: An update. Eur J Med Res [Internet]. 2020;25(1):1–6. Available from: https://doi.org/10.1186/s40001-020-00414-5
WHO. Update on coronavirus disease in Indonesia [Internet]. World Health Organization. 2021 [cited 2021 Jul 18]. Available from: https://www.who.int/indonesia/news/novel-coronavirus
Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020;92(9):1475–83.
Saha S, Kadam S. Convalescent plasma therapy - a silver lining for COVID-19 management? Hematol Transfus Cell Ther. 2021;43(2):201–11.
Rejeki MS, Sarnadi N, Wihastuti R, Fazharyasti V, Samin WY, Yudhaputri FA, et al. Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries. E Clinical Medicine [Internet]. 2021;36:100931. Available from: https://doi.org/10.1016/j.eclinm.2021.100931
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019
(COVID-19 ) Treatment Guidelines. Natl Institutes Heal [Internet]. 2021;July 8. Available from: https://www.covid19treatmentguidelines.nih.gov/
Food and Drug Administration. Recommendations for investigational COVID-19 convalescent plasma [Internet]. 2021 [cited 2021 Jul 19]. p. February 11. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-deviceexemption-ide-process- cber/recommendations-investigational-covid-19-convalescent-plasma
UHBFT. COVID-19 Quick Glance Guide for management of adult non-ICU patients at UHBFT. Univ Hosp Birmingham Found Trust. 2021;February 2(Version 8).
Australian National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19. 2021; Available from: www.covid19evidence.net.au
PDPI, PERKI, PAPDI, PERDATIN, IDAI. Protokol Tatalaksana COVID-19. 2021;14 Juli.
Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021;384(11):1015–27.
Food and Drug Administration. Recommendations for
investigational COVID-19 convalescent plasma
[Internet]. 2021 [cited 2021 Jul 19]. p. February 11. Available from: https://www.fda.gov/vaccines-bloodbiologics/investigational-new-drug-ind-ordeviceexemption-ide-process- cber/recommendationsinvestigational-covid-19-convalescent-plasma.
da Costa CBP, Martins FJ, da Cunha LER, Ratcli e NA, Cisne de Paula R, Castro HC. COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus. Int Immunopharmacol. 2021 Jan;90:107220. doi: 10.1016/j.intimp.2020.107220. Epub 2020 Nov 20. PMID: 33302034; PMCID: PMC7678452.
Duan K, Liu B, Li C, et al. E ectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020;117:9490-6.
Omrani AS, Zaqout A, Baiou A, et al. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report. J Med Virol 2020 September 23 (Epub ahead of print)17. UHBFT. COVID-19 Quick Glance Guide for management of adult non-ICU patients at UHBFT. Univ Hosp Birmingham Found Trust. 2021;February 2(Version 8).
Australian National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19. 2021; Available from: www. covid19evidence.net.au
PDPI, PERKI, PAPDI, PERDATIN, IDAI. Protokol Tatalaksana COVID-19. 2021;14 Juli.
Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-
N Engl J Med. 2021;384(11):1015–27.
Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest 2020;130:4791 -7.
Askenase PW. COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune
antibodies? J Extracell Vesicles. 2020 Oct;10(1):e12004. doi: 10.1002/jev2.12004. Epub 2020
Nov 14. PMID: 33304473; PMCID: PMC7710130.
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020; 371:m3939.
Perotti C, Baldanti F, Bruno R, et al. Mortality
reduction in 46 severe Covid-19 patients treated with
hyperimmune plasma: a proof of concept single arm
multicenter trial. Haematologica 2020;105: 2834-40.
Salazar E, Kuchipudi SV, Christensen PA, et al. Convalescent plasma anti-SARSCoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest 2020;130:6728-38.
Copyright (c) 2021 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
